GSK gets reprimanded by FDA for misleading advertising for Arzerra

[Guest guest]

GSK was reprimanded in a letter from the FDA, April 15th, 2010 for misleading

claims, among other things, in a product ad for Arzerra that appears in a

professional journal.

The FDA letter states:

" Specifically, the journal ad fails to reveal any of the risks associated with

the use of Arzerra. By omitting the most serious and frequently occurring risks,

the journal ad suggests that Arzerra is safer than has been demonstrated by

substantial evidence or substantial clinical experience. "

The complete letter is available here in .pdf format:

http://tinyurl.com/y3g3dbg

~chris

http://cllcanada.ca